By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Miscellaneous coagulation modifiers > Nuwiq (recombinant) > Nuwiq Dosage
Miscellaneous coagulation modifiers
https://themeditary.com/dosage-information/nuwiq-dosage-3545.html

Nuwiq Dosage

Drug Detail:Nuwiq (recombinant) (Antihemophilic factor (recombinant) [ ant-ee-hee-moe-fil-ik-fak-tor ])

Generic Name: Simoctocog Alfa 4000[iU] in 2.5mL;

Dosage Form: injection

Drug Class: Miscellaneous coagulation modifiers

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

For intravenous use after reconstitution

Dose

  • Each vial of NUWIQ is labeled with the actual Factor VIII potency expressed in international units (IU). One IU of Factor VIII activity is defined by the quantity of Factor VIII in one mL of normal human pooled plasma. Calculation of the required dose of Factor VIII is based on the empirical finding that 1 IU Factor VIII per kg body weight raises the plasma Factor VIII activity by approximately 2% of normal activity or 2 IU/dL when assessed using the one stage clotting assay. Use the following formulae to determine the required dose:
Image File


  • Dose and duration of therapy depend on the severity of the Factor VIII deficiency, the location and extent of the bleeding, FVIII level, and the patient’s clinical condition.

On-demand Treatment and Control of Bleeding Episodes

A guide for dosing NUWIQ for the on-demand treatment and control of bleeding episodes is provided in Table 1 . Selected dosing regimen should maintain plasma Factor VIII activity levels at or above the plasma levels (in % of normal or in IU/dL) outlined in the table.



Table 1: Dosing for Treatment and Control of Bleeding Episodes

Type of Bleeding Episodes Required peak post-infusion Factor VIII activity
(% of normal or IU/dL)
Frequency of Dosing (hours) Duration of Therapy (days)
Minor:
Superficial muscle or soft tissue and oral bleeds
20–40 12-24 At least 1 day, until the bleeding episode is resolved.
Moderate to Major:
Hemorrhage into muscles, into oral cavity, hemarthrosis, known trauma
30–60 12-24 For 3–4 days or more until bleeding episode is resolved.
Life-threatening: Intracranial, intra-abdominal, gastro-intestinal or intrathoracic bleeds, central nervous system bleeds, bleeding in retropharyngeal spaces or iliopsoas sheath, eyes/retina, fractures or head trauma 60–100 8-24 Until bleeding risk is resolved.

Perioperative Management

A guide for dosing NUWIQ during surgery (perioperative management) is provided in Table 2 . Dosing should aim at maintaining a plasma Factor VIII activity level at or above the plasma levels (in % of normal or in IU/dL) outlined in the table.


Table 2: Dosing for Perioperative Management

Type of Surgery Required post-infusion Factor VIII activity
(% of normal or IU/dL)
Frequency of Doses (hours) Duration of Therapy (days)
Minor
including tooth extraction
30–60
(pre- and post-operative)
24 At least 1 day, until healing is achieved.
Major
Intracranial, intra-abdominal, or joint-replacement therapy
80–100
(pre- and post-operative)
8-24 Until adequate wound healing, then continue therapy for at least another 7 days to maintain a Factor VIII activity of 30% to 60% (IU/dL).

Routine Prophylaxis

A guide for dosing NUWIQ for routine prophylaxis to reduce the frequency of bleeding is provided in Table 3 . Exact dosing should be defined by the patient’s clinical status and response.


Table 3: Dosing for Routine Prophylaxis

Subjects Dose (IU/kg) Frequency of infusions
Adults and adolescents [12 - 17 yrs] 30 - 40 Every other day
Children [2 - 11 yrs] 30 - 50 Every other day or three times per week

A regimen may be further individually adjusted to less or more frequent dosing at the discretion of the treating physician.


Preparation and Reconstitution

NUWIQ package contents:

  • single-use vial of NUWIQ concentrate
  • pre-filled syringe containing 2.5 mL Sterile Water for Injection
  • vial adapter
  • butterfly needle
  • two alcohol swabs.
  1. Always work on a clean surface and wash your hands before performing the procedure.
  2. Allow the vial of NUWIQ and the pre-filled syringe to come to room temperature.
  3. Remove the plastic flip-top cap from the NUWIQ vial to expose the rubber stopper. (Figure A).
  4. Wipe the top of the vial with an alcohol swab and allow the rubber stopper of the vial to dry.
  5. Peel back the paper cover from the vial adapter package revealing the adapter spike without removing the adapter from the package (Figure B).
  6. With the concentrate vial on an even surface, insert the adapter spike into the rubber stopper. The adapter snaps to the vial when done (Figure C).
  7. Peel back the paper cover from the pre-filled syringe package. Connect plunger rod attaching the threaded end of the plunger rod to the solvent syringe, turning clockwise until a slight resistance is felt (Figure D). Avoid contact with shaft.
  8. Break off the tamper-proof plastic tip from the syringe by snapping the perforation of the cap. Do not touch the inside of the cap or the syringe tip (Figure E).
  9. Remove the adapter packaging and connect the syringe to the vial adapter by turning clockwise until resistance is felt (Figure F).
  10. Slowly inject all liquid from syringe into the concentrate vial (Figure G).
  11. Without removing the syringe, dissolve the concentrate powder in the vial by gently moving or swirling a few times. DO NOT SHAKE. Wait until all the powder dissolves completely.
  12. Inspect the final solution for particles. The solution should be clear, colorless, and free from visible particles. Do not use if solution is cloudy or has particulate matter.
  13. Turn the vial and syringe upside down (still attached).
  14. Slowly withdraw the solution into the syringe. Make sure that all liquid is transferred to the syringe (Figure H).
  15. Detach the filled syringe from the vial adapter by turning counter clockwise.
Image File

Do not refrigerate the solution after reconstitution. Use the solution within 3 hours after reconstitution. If solution is not used within this time period, close the filled syringe with the tamper-proof plastic tip, and discard.


Administration

For intravenous use after reconstitution only

  1. Inspect the reconstituted NUWIQ solution for visible particulate matter and discoloration prior to administration. Do not use if particulate matter or discoloration is observed.
  2. Do not administer NUWIQ in the same tubing or container as other medications.
  3. Clean the chosen injection site with an alcohol swab.
  4. Attach the provided infusion set to the syringe. Insert the needle of the infusion set into the chosen vein.
  5. Perform intravenous bolus infusion. The rate of administration should be determined by patient’s comfort level, at a maximum rate of 4 mL per minute.
  6. After infusing NUWIQ, remove and properly discard the infusion set. After the infusion, remove the peel-off label containing the batch number from the factor concentrate vial and place it in the log book for record keeping.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by